Adrafinil

Adrafinil is a mild stimulant that is metabolized into Modafinil when taken. It therefore has almost the same effects as Modafinil, but is less powerful and takes longer to kick in.

adrafinil

Benefits:

  • Keeps you alert and awake for hours [1][2][3][4]
  • Increases concentration and attentiveness [5][4]
  • Mood booster, helpful for treatment of depression [6]
  • Treats bipolar disorder, cocaine dependence, parkinson’s disease, and schizophrenia [7][8][9][10][11]
  • Cognitive enhancer, improves working memory and pattern recognition [12][13][14][4]
  • Weight loss effects, reduces appetite [15]

What Is Adrafinil?

Adrafinil is a mild stimulant affecting the central nervous system. It is commonly used without a prescription by people who need to stay awake and alert for long periods of time. This nootropic is the prodrug to Modafinil. Because of this, Adrafinil and Modafinil have almost identical pharmacological effects.

Adrafinil was discovered in the late 1970’s by scientists working for the pharmaceutical company, Lafon. Lafon is the same company that later developed Modafinil. One huge difference between these two nootropics is that Modafinil is classified as a controlled substance in the United States while Adrafinil is not.

Adrafinil Dosage Information

A single 300mg tablet is sufficient for those trying to stay awake and focused for long periods of time. Dosages of 600 – 900mg will keep you much more awake and focused but increase the chance of unwanted side effects. People have reported severe insomnia following larger dosages of Adrafinil.

How Does Adrafinil Work?

Adrafinil is the prodrug to Modafinil. This means that Adrafinil is administered in an inactive form. Once ingested, this inactive form is metabolized into an active metabolite. In this case, Adrafinil is metabolized to Modafinil.

Once metabolized to Modafinil, it works in a similar fashion. Recent studies suggest that Modafinil affects dopamine transporters by inhibiting the breakdown of dopamine. This means that your body is not absorbing dopamine leading to much greater dopamine levels. [16] Greatly elevated dopamine levels result in Adrafinil having many nootropic properties.

Safety and Side Effects of Adrafinil

Even though Adrafinil is considered to be very safe it does carry certain side effects. Minor side effects include irritation or aggression, stomach pain and skin alteration. More serious side effects include liver disease, renal disorders.

I recommend that one only uses Adrafinil sparingly. Only use Adrafinil daily for prolonged periods of time under the supervision of a physician. It is also important to note that Adrafinil is on the list of substances prohibited for athletic competition by the World Anti-Doping Agency.

quoteicon

Adrafinil FAQ

Below are some of the most commonly asked questions about Adrafinil. If you have a question that’s not on this list, send it to us at questions@whatarenootropics.com and we will answer it for you.

Should I Use Adrafinil?

What Are Some Adrafinil Studies?

Cited Studies

1.  Erman MK, Rosenberg R, For The U S Modafinil Shift Work Sleep Disorder Study Group. “Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life.” Primary Care Companion to the Journal of Clinical Psychiatry 2007;9(3):188-94. Full Text

2.  Czeisler CA, Walsh JK, Roth T, Hughes RJ, Wright KP, Kingsbury L, Arora S, Schwartz JRL, Niebler GE, Dinges DF (August 2005). “Modafinil for Excessive Sleepiness Associated with Shift-Work Sleep Disorder”. N Engl J Med 353 (5): 476–486. doi:10.1056/NEJMoa041292. PMID 16079371. http://content.nejm.org/cgi/content/abstract/353/5/476.

3.  Provigil (Modafinil) Site.” 24 December 1998 [1]

4.  http://www.ncbi.nlm.nih.gov/pubmed/11191710

5.  Biederman J, Pliszka SR (March 2008). “Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents”. J. Pediatr. 152 (3): 394–9. doi:10.1016/j.jpeds.2007.07.052. PMID 18280848

6.  Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ (2007). “Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness”. Ann Clin Psychiatry 19 (3): 153–9. doi:10.1080/10401230701464858. PMID 17729016

7. http://ajp.psychiatryonline.org/cgi/content/full/164/8/1242

8. PMID 20673554.

9. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O’Brien CP (January 2005). “A double-blind, placebo-controlled trial of modafinil for cocaine dependence”. Neuropsychopharmacology 30 (1): 205–11. doi:10.1038/sj.npp.1300600. PMID 15525998

10. van Vliet SA, Vanwersch RA, Jongsma MJ, van der Gugten J, Olivier B, Philippens IH (September 2006). “Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects”. Behav Pharmacol 17 (5–6): 453–62. doi:10.1097/00008877-200609000-00011. PMID 16940766

11. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (July 2004). “Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia”. Neuropsychopharmacology 29 (7): 1363–73. doi:10.1038/sj.npp.1300457. PMID 15085092

12. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003). “Cognitive enhancing effects of modafinil in healthy volunteers”. Psychopharmacology (Berl.) 165 (3): 260–9. doi:10.1007/s00213-002-1250-8. PMID 12417966

13. Randall DC, Viswanath A, Bharania P, Elsabagh SM, Hartley DE, Shneerson JM, File SE (2005). “Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived?”. J Clin Psychopharmacol 25 (2): 175–9. doi:10.1097/01.jcp.0000155816.21467.25. PMID 15738750

14. Baranski JV, Pigeau R, Dinich P, Jacobs I (2004). “Effects of modafinil on cognitive and meta-cognitive performance”. Hum Psychopharmacol 19 (5): 323–32. doi:10.1002/hup.596. PMID 15252824

15. Perez GA, Haney M, Foltin RW, Hart CL. (October 2008). “Modafinil decreases food intake in humans subjected to simulated shift work”. Pharmacol Biochem Behav 90 (4): 717–22. doi:10.1016/j.pbb.2008.05.018. PMID 18573275

16. Zolkowska, D.; Jain, R.; Rothman, R. B.; Partilla, J. S.; Roth, B. L.; Setola, V.; Prisinzano, T. E.; Baumann, M. H. (2009). “Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.”. The Journal of pharmacology and experimental therapeutics 329 (2): 738–746. doi:10.1124/jpet.108.146142. PMC 2672878. PMID 19197004

Disclaimer: No statements on this website have been reviewed by the Food and Drug Administration. No products mentioned on this website are intended to diagnose, treat, cure or prevent any diseases. All editorials on this site were written by volunteer editors and do not claim or state to be medical professionals giving medical advice. This website is only for the purpose of providing information. Please consult with your doctor before starting any mental health programs or dietary supplements. If you feel any of this informtion is inaccurate contact us and we will verify and implement your correction within about 48 business hours. Also note that we have multiple affiliates and we are paid commission on various products by different compagnies and or advertisers. If you wish to advertise with us, please contact us. Any and all trademarks, logos and service makrs displayed on this site are registered or unregistered Trademarks of their respective owners.